ClinicalTrials.gov
Cure8 trial brief
Why This Matters
People with UC in remission who still have gut–brain interaction symptoms often look for safe ways to improve symptoms or gut microbiota balance.
This trial tests a targeted bacterial supplement and will measure both microbiome changes and clinical markers (fecal calprotectin, symptom scores), which could be relevant if results show clinical benefit and safety.
Who Should Pay Attention
Adults with ulcerative colitis in remission who have IBS-like symptoms or other DGBI; gastroenterology clinicians and researchers interested in microbiome-targeted supplements and biomarker-based outcomes.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment50 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a not-yet-recruiting randomized, double-blind, placebo-controlled crossover trial based at the University of Padova planning to enroll about 50 participants aged 18–70 with confirmed UC in remission and concurrent DGBI. Participants will take two tablets per day of Colipral (E. coli 5C LMG S-33222) or matching placebo for 60 days, then cross over.
Primary outcomes focus on microbiota composition (16S rRNA from stool); secondary outcomes include fecal calprotectin and validated symptom and quality-of-life questionnaires (IBDQ, IBS-SSS, VAS, Bristol Stool Scale). Design notes: Because this is a trial record, there are no reported results here.
The trial excludes recent antibiotic or probiotic use and people on restrictive diets, and it requires remission for at least six months. Enrollment status at the time of the record is not-yet-recruiting.
Keep In Mind
This is a registered interventional trial record without posted results; planned enrollment is ~50 and the study is not yet recruiting. The primary outcome is microbiome composition by 16S sequencing — changes there do not necessarily translate into clinical benefit.
the intervention is labeled as a food supplement and the trial excludes recent antibiotic/probiotic users and those on restrictive diets.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorUniversity of Padova
Trial IDNCT07751081
Study typeInterventional
Trial phaseNA
Enrollment50 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 7, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A very common vitamin has surprised scientists and is forcing them to rethink how to manage inflammation in Crohn’s disease and colitis
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Reduced fecal GP2 levels in ulcerative colitis associate with inflammatory activity and microbial composition.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...